Navigation Links
Novel pathway regulating angiogenesis may fight retinal disease, cancers

CINCINNATI Scientists identify in the journal Nature a new molecular pathway used to suppress blood vessel branching in the developing retina a finding with potential therapeutic value for fighting diseases of the retina and a variety of cancers.

Researchers report that myeloid cells, blood cells involved in the immune system, use this molecular pathway to guide blood vessel patterning in the retina. Furthermore, in the same study researchers were able to reverse this pathway to accelerate the growth of branching vessels, which could be important to developing new methods for repairing damaged tissues.

"We show in the setting of retina that myeloid cells use this pathway to direct vascular traffic," explained Richard Lang Ph.D., senior investigator on the study and director of the Visual Systems Group in the Division of Ophthalmology at Cincinnati Children's Hospital Medical Center. "We think modulation of this pathway might become a promising therapeutic option.''

The study, to be published online May 29, demonstrates how retinal myeloid cells regulate blood vessel branching in the still-developing retinas of postnatal mice by using the Wnt protein signaling network. The Wnt pathway is known for its role in embryonic and early development as well as in cancer. Although myeloid cells play an important part in the immune system, these cells are also found in many different tumor types and promote tumor progression.

Through a series of experiments in cell cultures and mouse models, researchers determined the new pathway works by myeloid cells utilizing the Wnt pathway to regulate expression of a gene known as Flt1. Flt1 encodes a protein called vascular endothelial growth factor receptor-1 (VEGFR1), which suppresses vascular growth by binding vascular endothelial growth factor (VEGF). The expression of Flt1 can be adjusted so that when ramped up it inhibits VEGF and vascular branching, or when turned down it allows VEGF to increase branching.

Dr. Lang said the Wnt-Flt1 response is a new pathway for regulating VEGF-stimulated angiogenesis (blood vessel formation). This presents a number of new research opportunities to test its influence on retinal diseases that are often associated with abnormal blood vessel development and in tumor formation, he added.


Contact: Nick Miller
Cincinnati Children's Hospital Medical Center

Related biology news :

1. GW researchers reveal 18 novel subtype-dependent genetic variants for autism spectrum disorders and identify potential genetic markers for diagnostic screening
2. Novel ash analysis validates volcano no-fly zones
3. Novel therapy improves immune function in teen with rare disease
4. Data suggest liver experts should take care when prescribing novel antiviral HCV drugs
5. Novel method could improve the performance of proteins used therapeutically
6. Synthetic biology: TUM researchers develop novel kind of fluorescent protein
7. Team creates novel vaccine that produces strong immunity against cocaine high
8. Novel compounds show early promise in treatment of Parkinsons, Huntingtons, Alzheimers
9. GEN co-sponsors roundtable discussion on novel bioremediation techniques
10. In the lab, engineers novel liquid provides a solid fix for broken bones
11. Novel services for tropical forest monitoring with satellite
Post Your Comments:
(Date:10/26/2015)... and LAS VEGAS , Oct. ... Labs , an innovator in modern authentication and a ... announced the launch of its latest version of the ... enabling organizations to use standards-based authentication that supports existing ... S3 Authentication Suite is ideal for organizations deploying customer-facing ...
(Date:10/23/2015)... , Oct. 23, 2015 Research and ... the "Global Voice Recognition Biometrics Market 2015-2019" ... --> The global voice recognition biometrics ... 2014-2019. --> --> ... has been prepared based on an in-depth market analysis ...
(Date:10/22/2015)... 22, 2015  Aware, Inc. (NASDAQ: AWRE ), a leading ... its third quarter ended September 30, 2015.  ... 2015 was $4.0 million, a decrease of 33% compared to $6.0 ... third quarter of 2015 was $2.2 million, or $0.10 per diluted ... in the same period a year ago.  ...
Breaking Biology News(10 mins):
(Date:11/26/2015)... MUMBAI , November 26, 2015 ... --> Accutest Research ... accredited Contract Research Organization (CRO), has ... Chase Cancer Center - Temple Health ... ,     (Photo: ) ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... business and prospects remain fundamentally strong and highlights ... doxorubicin) recently received DSMB recommendation to continue the ... review of the final interim efficacy and safety ... Endpoint in men with heavily pretreated castration- and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
Breaking Biology Technology: